Pharmaceutical stocks are expected to remain in focus as competition in the domestic market picks up pace following the patent expiry of Semaglutide, a widely prescribed drug for diabetes and weight management. The entry of multiple Indian companies into this space is already triggering a sharp correction in prices, making the treatment more affordable for patients.
Globally, Semaglutide is sold under popular brands such as Ozempic and Wegovy by Novo Nordisk. While the drug has gained strong traction due to its effectiveness, high costs have remained a major barrier. With patent protection ending, that landscape is now changing as Indian pharmaceutical companies introduce lower-cost alternatives.
The price variation across offerings is notable. Entry-level monthly treatments are now available for roughly Rs 1,300 to Rs 2,200, while some advanced or premium formats are priced between Rs 3600 and Rs 4200. In one of the most aggressive moves, Natco Pharma has priced its multi-dose vial at about Rs 1,290, with its pen-based version going up to around Rs 4000.
Companies are also differentiating themselves through product formats and positioning. Torrent Pharmaceuticals has introduced an oral version, which could eliminate the need for injections. Alkem Laboratories is targeting the value segment with a pen device priced near Rs 1800. Sun Pharmaceutical Industries is focusing on premium offerings with multiple dosage options and added patient support services. Meanwhile, Zydus Lifesciences and Glenmark Pharmaceuticals are aiming at the mid and mass segments with competitively priced options. Dr. Reddy’s Laboratories, on the other hand, is packaging the drug with a broader care ecosystem.
With competition intensifying and prices falling sharply, the availability of Semaglutide is set to expand significantly in India, offering relief to patients who previously found the treatment expensive.
(Disclaimer: The above article is meant for informational purposes only and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions)
